MSTN and neuromuscular disease caused by qualitative or quantitative defects of dystrophin: Our data support the observation that the two dystrophinopathy patients who presented advanced muscle atrophy are the only cases showing reduced myostatin levels, that correlated with their reduced muscle mass.